Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Costacurta

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Protocols|December 23, 2024
Using Vesicular Stomatitis Virus as a Platform for Directed Protease EvolutionFrancesco Costacurta, Stefanie Rauch, Dorothee von Laer, et al.
Current Protocols|November 21, 2024
Vesicular Stomatitis Virus as a Platform for Protease Activity MeasurementsStefanie Rauch, Francesco Costacurta, Dorothee von Laer, et al.
Communications Biology|April 28, 2022
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibitionEmmanuel Heilmann, Francesco Costacurta, Stephan Geley, et al.
Npj Viruses|February 23, 2026
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvirLaura Krismer, Helge Schöppe, Stefanie Rauch, et al.
Npj Viruses|June 27, 2024
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvirLaura Krismer, Helge Schöppe, Stefanie Rauch, et al.
Science Translational Medicine|October 4, 2022
SARS-CoV-2 3CL<sup>pro</sup> mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, et al.
Science Advances|March 29, 2023
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSeyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Biorxiv : the Preprint Server for Biology|August 19, 2022
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSeyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Antiviral Research|July 25, 2024
Highly specific SARS-CoV-2 main protease (M<sup>pro</sup>) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based systemStefanie Rauch, Francesco Costacurta, Helge Schöppe, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
A comprehensive study of SARS-CoV-2 main protease (M<sup>pro</sup>) inhibitor-resistant mutants selected in a VSV-based systemFrancesco Costacurta, Andrea Dodaro, David Bante, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Protocols|December 23, 2024
Using Vesicular Stomatitis Virus as a Platform for Directed Protease EvolutionFrancesco Costacurta, Stefanie Rauch, Dorothee von Laer, et al.
Current Protocols|November 21, 2024
Vesicular Stomatitis Virus as a Platform for Protease Activity MeasurementsStefanie Rauch, Francesco Costacurta, Dorothee von Laer, et al.
Communications Biology|April 28, 2022
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibitionEmmanuel Heilmann, Francesco Costacurta, Stephan Geley, et al.
Npj Viruses|February 23, 2026
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvirLaura Krismer, Helge Schöppe, Stefanie Rauch, et al.
Npj Viruses|June 27, 2024
Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvirLaura Krismer, Helge Schöppe, Stefanie Rauch, et al.
Science Translational Medicine|October 4, 2022
SARS-CoV-2 3CL<sup>pro</sup> mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, et al.
Science Advances|March 29, 2023
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSeyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Biorxiv : the Preprint Server for Biology|August 19, 2022
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSeyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Antiviral Research|July 25, 2024
Highly specific SARS-CoV-2 main protease (M<sup>pro</sup>) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based systemStefanie Rauch, Francesco Costacurta, Helge Schöppe, et al.
Biorxiv : the Preprint Server for Biology|October 9, 2023
A comprehensive study of SARS-CoV-2 main protease (M<sup>pro</sup>) inhibitor-resistant mutants selected in a VSV-based systemFrancesco Costacurta, Andrea Dodaro, David Bante, et al.
Pageof 2